Tammara V, Mahmood I, Yu D K, Hileman G A
Division of Pharmaceutical Evaluation I, Food & Drug Administration, Rockville, Maryland 20852, USA.
Ther Drug Monit. 1997 Feb;19(1):79-82. doi: 10.1097/00007691-199702000-00014.
A limited sampling model (LSM) was developed to estimate the area under the curve (AUC) and maximum plasma concentration (Cmax) for a 1-g oral dose of vigabatrin. The model was developed using the data from 10 healthy subjects and one time point. The following equations describe the model for AUC and Cmax: AUC(predicted) = 5.4 x C3h + 70 and Cmax(predicted) = 0.18 x AUC(0-infinity) + 9.4. The model was validated in 49 subjects who orally received 1-g vigabatrin. This LSM was also used to predict AUC and Cmax volunteers who received 2- and 4-g vigabatrin doses and in renal failure patients who were given a 0.75-g dose. The model provided good estimates of both AUC and Cmax in all groups of subjects except renal dysfunction patients. The method described here may be used to estimate AUC and Cmax of vigabatrin without detailed pharmacokinetic studies.
开发了一种有限采样模型(LSM),用于估计1克口服剂量的vigabatrin的曲线下面积(AUC)和最大血浆浓度(Cmax)。该模型利用10名健康受试者的数据和一个时间点开发而成。以下方程描述了AUC和Cmax的模型:AUC(预测值)=5.4×C3h + 70,Cmax(预测值)=0.18×AUC(0至无穷大)+ 9.4。该模型在49名口服1克vigabatrin的受试者中得到验证。此LSM还用于预测接受2克和4克vigabatrin剂量的志愿者以及接受0.75克剂量的肾衰竭患者的AUC和Cmax。除肾功能不全患者外,该模型在所有受试者组中均能对AUC和Cmax进行良好估计。此处描述的方法可用于在无需详细药代动力学研究的情况下估计vigabatrin的AUC和Cmax。